BioSpace News Archive

Children’s Hospital of Philadelphia announced it has received $1 million from Pediatric Cancer Foundation, an organization that has been raising funds for research since 1970 to support doctors and hospitals in an effort to eradicate childhood cancer.

Allurion, a company dedicated to ending obesity, today announced results from a 232-patient study investigating the Allurion Program.

Appia Bio, Inc. today announced the appointments of Sylvaine Cases, Ph.D. as chief business officer (CBO) and Alex Babayan, Ph.D. as vice president, head of regulatory affairs.

Renowned pediatric cardiovascular surgeon Dr. Joseph M. Forbess has joined Nicklaus Children’s Pediatric Specialists (NCPS) as chief of the Section of Cardiovascular (CV) Surgery, and assumes a leadership position within the Nicklaus Children’s Heart Institute.

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA on 6 June 2023 regarding the Company’s acquisition of Thor Medical AS, with approval of the Transaction from the Company’s annual general meeting as one of the closing conditions.

Medline announced that after more than 26 years of leadership, Charlie Mills, Andy Mills and Jim Abrams will retire from their current roles.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the proprietary Accum™-based platform, which Defence is harnessing to develop innovative therapeutics and prophylactics against cancers and infectious diseases.

The Alberta Cancer Foundation, Alberta Health Services and the University of Calgary are thrilled to announce a historic and transformational $50 million donation to the Calgary Cancer Centre from the Arthur J.E. Child Foundation.

Microbot Medical Inc. announced that it closed its previously announced registered direct offering for the purchase and sale of 624,618 shares of the Company’s common stock at a purchase price of $3.25 per share of common stock priced at-the-market under Nasdaq rules.

Phaxiam Therapeutics, announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES.